ArticleFrontiers in immunology2025
Serum lactate dehydrogenase and rapidly progressive interstitial lung disease are associated with increased mortality in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and laboratory predictors of diagnostic efficacy ofRheumatology international · 2026Article
- Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort.Biomedicines · 2026Article
- Spectrum of autoantibodies and other serological parameters in connective tissue disease-associated interstitial lung disease patients.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the clinical characteristics and prognostic significance of serum lactate dehydrogenase (LDH) in patients with anti-MDA5+ dermatomyositis (anti-MDA5+ DM). Methods: We assessed 246 consecutive patients with anti-MDA5+ DM. The patients were divided into two groups based on LDH levels: the LDH ≤ 338 U/L group and the LDH > 338 U/L group. We compared the clinical characteristics, laboratory findings, and long-term prognosis between the two groups. Results: Overall, the one-year mortality rate in patients with anti-MDA5+ DM was high, at 24.39% (60/246). LDH levels exhibited a nonlinear, inverted S-shaped relationship with the overall mortality risk in anti-MDA5+ DM patients (nonlinear P = 0.001). Patients in the LDH > 338 U/L group had significantly higher levels of ALT [64.0 (32.0, 121.0) vs 40.0 (23.0, 66.5), P<0.001], AST [75.0 (47.5, 134.0) vs 40.0 (26.0, 60.6), P<0.001], CK [107.0 (42.0, 208.8) vs 50.0 (35.5, 100.5), P<0.001], CRP [8.5 (3.5, 17.6) vs 4.7 (2.7, 10.2), P<0.001], and serum ferritin levels [1307.6 (679.8, 1565.5) vs 1001.0 (391.2, 1307.6), P<0.001] compared to the LDH ≤ 338 U/L group. Additionally, the positivity rate of Anti-Ro52 antibodies (70.7% vs 57.7%, P = 0.033), the incidence of rapidly progressive interstitial lung disease (RPILD) (42.3% vs 29.3%, P = 0.033), and the mortality rate (35.0% vs 13.8%, P<0.001) were significantly higher in the LDH > 338 U/L group than in the LDH ≤ 338 U/L group. Multivariable regression analysis revealed that LDH > 338 U/L and the presence of RPILD were associated with poor prognosis [hazard ratios of 2.253 (95% CI 1.258, 4.035, P = 0.006) and 10.293 (95% CI 4.683, 22.623, P < 0.001), respectively]. Conclusion: Patients with different LDH levels exhibit distinct clinical characteristics, laboratory findings, and long-term prognosis. Elevated LDH levels (> 338 U/L) and the presence of RPILD are associated with poor prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.